RecruitingPhase 2NCT05074355

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Vikas Gupta, M.D.
Princess Margaret Cancer Centre
Intervention
Azacitidine(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05074355 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm →

← Back to all trials